Hillhurst Bio secures $1.9 million phase 2 SBIR grant to advance preclinical work in diabetic retinopathy
SAN DIEGO, CA (March 28, 2025) – Hillhurst ...
Hillhurst Biopharmaceuticals receives NIH Heal Initiative Award for development of HBI-201 in pain
SAN DIEGO, CA (November 7, 2023) Hillhurst Biopharmaceuticals, ...
Hillhurst Biopharmaceuticals receives $3 million in NIH SBIR funding for Phase 2a clinical study in sickle cell disease
SAN DIEGO, CA (September 20, 2023) Hillhurst Biopharmaceuticals, ...
Hillhurst Biopharmaceuticals announces completion of last patient last visit in Phase 1 clinical trial of HBI-002
SAN DIEGO, CA (May 23, 2023) Hillhurst Biopharmaceuticals, ...
Drops and drugs for diabetic vison loss
Eye injections are the only way to treat diabetic ...
Hillhurst Bio Turns Gas from Poisonous to Therapeutic
When most people think of carbon monoxide, they envision odorless ...
Hillhurst Biopharmaceuticals announces first subject dosed in Phase 1 clinical trial of HBI-002
SAN DIEGO, CA (July 26, 2022) Hillhurst Biopharmaceuticals, ...
Deadly gas could treat diabetic blindness, according to AU study
Carbon monoxide from engine exhaust kills hundreds of people ...
Hillhurst Biopharmaceuticals receives NIH grant to collaborate with Massachussetts General Hospital for the development of HBI-002 for Parkinson’s disease
SAN DIEGO, CA (September 22, 2021) Hillhurst Biopharmaceuticals, ...
Hillhurst Biopharmaceuticals receives funding for development of HBI-002 for the treatment of diabetic retinopathy
SAN DIEGO, CA (September 14, 2023) Hillhurst Biopharmaceuticals, ...